Veru Inc (VERU) Stock Price, Quote & News

Company Profile

Veru Inc., a late clinical stage biopharmaceutical company, focuses on developing medicines for treatment of metabolic diseases, oncology, and viral-induced acute respiratory distress syndrome (ARDS) in Florida and internationally. It provides FC2 female condom for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. The company develops enobosarm, a selective androgen receptor modulator for treatment of augment fat loss and to prevent muscle l...

Industry: Biotechnology

Sector: Healthcare

Phone: 305 509 6897

Website: verupharma.com

Address:

2916 North Miami Avenue, Suite 1000, Miami, United States

mrkymrk Jan. 14 at 1:02 PM

$VERU they don’t just need to decide on what drug they are going to use in their next trial. They need to actually sign a partnership with that company. Or better yet and acquisiton. That’s the only way this things jumps in the next 12 months and shows signs promise.

0 · Reply

brucetreez Jan. 14 at 5:08 AM

$VERU somethings gotta give

0 · Reply

TradeHawk Jan. 13 at 6:02 PM

$VERU A new positive peer-reviewed article was published in the MDPI Cells journal about Veru's VERU-111 drug candidate. "VERU-111 Promotes an Anti-Tumor Response Through Restoration of Gut Microbial Homeostasis and Associated Metabolic Dysregulation". https://www.mdpi.com/2073-4409/15/2/141

1 · Reply

love_bioatla Jan. 10 at 6:44 AM

$VERU go vreu

1 · Reply

mrkymrk Jan. 9 at 2:10 PM

$VERU Plateau trial still not registered on clinical http://trials.gov. I’ll say it again, WTF do these people do all day? 22 people on payroll and everything always in limbo. What a fucking hoax. It takes no more than 4 people to negotiate a deal with Lily or Novo. A commercial lead, legal lead, finance lead, medical lead. That’s it!!!

0 · Reply

mrkymrk Jan. 7 at 3:14 PM

$VERU all these deals happening in the hottest space in bio (oral GLP) and no one wants this trash!! Management should all be fired for letting this dwindle to $35M market cap while constantly blaming FDA and others for their lack of leadership and prudent decision making.

0 · Reply

WallStreetBuyDip Jan. 5 at 5:14 AM

How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.

0 · Reply

SuperGreenToday Dec. 30 at 5:06 PM

$VERU Share Price: $2.14 Contract Selected: Jan 23, 2026 $2.5 Calls Buy Zone: $0.34 – $0.43 Target Zone: $0.57 – $0.69 Potential Upside: 56% ROI Time to Expiration: 23 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

Eesnimi Dec. 30 at 3:23 PM

$VERU Goal of the company is to scam investor money to get high salary for years. For that every 3-4 years comes new magic pill idea

0 · Reply

Eesnimi Dec. 30 at 3:18 PM

$VERU All time low, price is in freefall . +1500% up would be barely enough for recovery

0 · Reply

Veru Inc. (VERU) Q4 2025 Earnings Call Transcript

Dec 17, 2025, 6:30 AM EST - 4 weeks ago

Veru Reports Fiscal Year 2025 Financial Results and Clinical Program Progress

Dec 10, 2025, 8:30 AM EST - 5 weeks ago

Veru to Report Fiscal Year 2025 Financial Results on December 17th

Oct 31, 2025, 8:30 AM EDT - 2 months ago

Veru to Present Two Abstracts at ObesityWeek 2025

Oct 29, 2025, 4:01 PM EDT - 2 months ago

Veru Announces Proposed Public Offering

Sep 23, 2025, 8:30 AM EDT - 4 months ago

Veru Announces Successful FDA Meeting Providing Regulatory Clarity for Enobosarm for Muscle Preservation in Combination with GLP-1 RA for Greater Weight Loss in the Treatment of Obesity

Aug 12, 2025, 12:57 PM EDT - 5 months ago

Veru Inc. (VERU) Q3 2025 Earnings Call Transcript

Aug 12, 2025, 6:30 AM EDT - 5 months ago

Veru Reports Fiscal 2025 Third Quarter Financial Results and Clinical Program Progress

Aug 11, 2025, 8:30 AM EDT - 5 months ago

Veru Announces Selection of Novel Modified Release Oral Enobosarm Formulation for Chronic Weight Loss Management Following Pharmacokinetic Clinical Study

Aug 6, 2025, 8:30 AM EDT - 5 months ago

Veru Announces Reverse Stock Split

Jul 22, 2025, 8:30 AM EDT - 6 months ago

Veru to Participate in the 2025 BTIG Virtual Biotech Conference

Jun 11, 2025, 8:30 AM EDT - 7 months ago

Veru to Participate in the Virtual BTIG Obesity Health Forum

May 28, 2025, 12:11 PM EDT - 8 months ago

Veru's Enobosarm Shows Muscle In Wegovy Combo Trial

May 28, 2025, 6:30 AM EDT - 8 months ago

Veru Reports Positive Safety Results from Phase 2b QUALITY Study: Enobosarm Added to Semaglutide Led to Greater Fat Loss, Preservation of Muscle, and Fewer Gastrointestinal Side Effects Compared to Semaglutide Alone

May 26, 2025, 9:36 PM EDT - 8 months ago

Veru: Saving Muscle Mass Amidst The GLP-1 Drug Boom

May 8, 2025, 12:42 PM EDT - 8 months ago

Veru Inc. (VERU) Q2 2025 Earnings Call Transcript

May 8, 2025, 9:30 AM EDT - 8 months ago

JTC Team Hosts Virtual Investor "KOL Connect" Segment to Discuss Veru Inc.'s (NASDAQ:VERU) Enobosarm Taking GLP-1 Weight Loss to Next Level

May 8, 2025, 9:25 AM EDT - 8 months ago

Veru Participates in a Virtual Investor KOL Connect Segment

May 8, 2025, 6:30 AM EDT - 8 months ago

Veru Reports Fiscal 2025 Second Quarter Financial Results and Clinical Program Progress

May 1, 2025, 8:30 AM EDT - 9 months ago

Veru to Report Fiscal 2025 Second Quarter Financial Results on May 8

Apr 16, 2025, 8:30 AM EDT - 9 months ago

Veru to Present at the 2nd Annual GLP-1-Based Therapeutics Summit

Mar 31, 2025, 8:30 AM EDT - 10 months ago

Veru to Participate in Fireside Chat at the Jones Healthcare and Technology Innovation Conference

Feb 19, 2025, 10:41 AM EST - 11 months ago

Fat, not muscle: Drugmakers in race for next weight-loss breakthrough

ARWR AZN BHVN KROS LLY NVO REGN

Feb 13, 2025, 2:35 PM EST - 11 months ago

Veru Inc (VERU) Q1 2025 Earnings Call Transcript

Feb 13, 2025, 6:30 AM EST - 11 months ago

Veru Reports Fiscal 2025 First Quarter Financial Results and Clinical Program Progress

Jan 27, 2025, 10:34 AM EST - 1 year ago

Veru Shares Tumble Despite Enobosarm's Lean Muscle Preservation Breakthrough

Jan 27, 2025, 6:30 AM EST - 1 year ago

Veru Announces Positive Topline Data from Phase 2b QUALITY Clinical Study: Enobosarm Preserved Lean Mass in Patients Receiving WEGOVY® (Semaglutide) for Weight Reduction

Dec 31, 2024, 8:30 AM EST - 1 year ago

Veru Announces the Sale of the FC2 Female Condom® (Internal Condom) Business

Nov 26, 2024, 8:30 AM EST - 1 year ago

Veru to Present at the 17th International Conference of the Society on Sarcopenia, Cachexia, & Wasting Disorders

Nov 5, 2024, 8:30 AM EST - 1 year ago

Veru Announces Meta-analysis of Body Composition Data from Older Patients with Obesity which Supports Potential for Enobosarm to Optimize Weight Loss at ObesityWeek

Oct 21, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at ObesityWeek: Meta-Analysis of 4 Previous Randomized Clinical Trials that Support the Potential of Enobosarm to Optimize Weight Loss

Oct 16, 2024, 8:30 AM EDT - 1 year ago

Veru to Deliver Keynote Presentation on the Scientific Support for Enobosarm in Combination with GLP-1 Receptor Agonist to Preserve Muscle for Higher Quality Weight Loss at the 4th Edition of the World Obesity and Weight Management Congress

Sep 11, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the 2024 Cantor Global Healthcare Conference

Aug 10, 2024, 8:39 AM EDT - 1 year ago

Veru Inc. (VERU) Q3 2024 Earnings Call Transcript

Aug 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reaches Full Enrollment for Phase 2b QUALITY Clinical Study of Enobosarm for Obesity and Reports Fiscal 2024 Third Quarter Financial Results

Aug 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Third Quarter Financial Results on August 8, 2024

Jul 29, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the BTIG Virtual Biotechnology Conference

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Participate in the Leerink Therapeutics Forum: I&I and Metabolism

Jun 24, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Safety and Body Composition Data from Two Late-Breaker Presentations at the American Diabetes Association's 84th Scientific Sessions

Jun 18, 2024, 4:05 PM EDT - 1 year ago

Veru Adjourns 2024 Annual Meeting of Shareholders to June 27, 2024

Jun 17, 2024, 4:45 PM EDT - 1 year ago

Veru Reminds Shareholders to Vote in Advance of Tomorrow's Deadline for 2024 Annual Meeting of Shareholders

Jun 10, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Diabetes Association's 84th Scientific Sessions

May 22, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the Jefferies Global Healthcare Conference

May 15, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Steven B. Heymsfield M.D.

May 14, 2024, 8:30 AM EDT - 1 year ago

Veru Announces Mitchell Steiner as Keynote Speaker at Biomed Israel 2024: The 22nd National Life Science & Technology Week

May 8, 2024, 6:30 AM EDT - 1 year ago

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

May 2, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the GLP-1 Based Therapeutics Summit

May 1, 2024, 8:30 AM EDT - 1 year ago

Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

Apr 30, 2024, 8:30 AM EDT - 1 year ago

Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

Apr 25, 2024, 8:30 AM EDT - 1 year ago

Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

mrkymrk Jan. 14 at 1:02 PM

0 · Reply

brucetreez Jan. 14 at 5:08 AM

$VERU somethings gotta give

0 · Reply

TradeHawk Jan. 13 at 6:02 PM

1 · Reply

love_bioatla Jan. 10 at 6:44 AM

$VERU go vreu

1 · Reply

mrkymrk Jan. 9 at 2:10 PM

0 · Reply

mrkymrk Jan. 7 at 3:14 PM

0 · Reply

WallStreetBuyDip Jan. 5 at 5:14 AM

How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.

0 · Reply

SuperGreenToday Dec. 30 at 5:06 PM

0 · Reply

Eesnimi Dec. 30 at 3:23 PM

$VERU Goal of the company is to scam investor money to get high salary for years. For that every 3-4 years comes new magic pill idea

0 · Reply

Eesnimi Dec. 30 at 3:18 PM

$VERU All time low, price is in freefall . +1500% up would be barely enough for recovery

0 · Reply

AuctionAxis Dec. 25 at 4:38 PM

$VERU Market behavior suggests the name is transitioning from speculation toward proof‑based evaluation. Cash flow visibility will determine how patient investors remain. Visible traction across segments would strengthen the thesis. Success from here is primarily about discipline, not discovery.

0 · Reply

WallStreetBuyDip Dec. 23 at 3:43 PM

How do you trade small and mid cap stocks? I buy when H% is low. Nothing else. I keep track of my results to see if my strategy worked out or not. $BBIG + $VERU will trade the same.

0 · Reply

mrkymrk Dec. 23 at 3:05 PM

$VERU Novo’s oral GLP getting approved should be good news for VERU. Pharma’s are making the move to oral in GLP space. Why then would they want to pair that with an injection for muscle retention? A muscle retention combo with another oral agent makes the most sense. Why VErU management is unable to make the case to potential suitors is BEYOND ME! This is why they need replaced immediately. They are incompetent and ALWAYS blaming someone else for their failures and poor decision making.

0 · Reply

inmarketswetrust Dec. 21 at 5:27 PM

$VERU from seeking alpha this am. Will see what cannacord thinks is worth $25/share. Not optimistic on this one but maybe we get a surprise partnership/ cash infusion/BO. So far this has done nothing but incinerate my money

0 · Reply

inmarketswetrust Dec. 21 at 5:21 PM

$VERU promising drug- weak management. Very few PhD/MDs have the DNA to be an excellent CEO and grow a company. This guy is a doctor, no more. He’s not a leader. Go listen to him speak: half the time he goes full Joe Biden and trips all over his own words. Early dementia? Who knows for sure, but it doesn’t scream competency. For that reason I won’t hold this stock. Best case scenario: drug gets sold to someone that knows how to monetize it. In fact, why isn’t it already sold? He has no money for Phase 3- it’s a great add on to Ozempic-he must be holding out for insane valuations. He’s mumbling old man with no CEO/biz dev skills.

0 · Reply

mrkymrk Dec. 18 at 6:31 PM

$VERU and it’s down. WTF. This management team are the biggest, most useless pieces of shit ever.

1 · Reply

okokYourSoSmart Dec. 18 at 5:53 PM

$VERU doesn’t their endosarm drug spare the muscle when taken with ozempic? And also Improve the side effects? That sounds huge to me idk.

2 · Reply

mrkymrk Dec. 18 at 1:39 PM

$VERU up on 500K volume pre market???? 😳

0 · Reply

Stock_Catcher Dec. 18 at 1:08 PM

$VERU perking

0 · Reply

BioTechChap Dec. 18 at 1:05 PM

$VERU This is significantly bullish. At least someone positive.

0 · Reply

DylanGFM Dec. 18 at 1:03 PM

$FCEL $VERU $ATHA all popping up same time !!!

0 · Reply

DylanGFM Dec. 18 at 1:00 PM

$VERU s-8 form and FDA guidance from yesterday probably fueling this. Lot of selling idk

0 · Reply

Market Cap	36.43M
Revenue (ttm)	0.00
Net Income (ttm)	-22.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	65,141
Avg Vol	168,492
Day's Range	N/A - N/A
Shares Out	16.05M
Stochastic %K	79%
Beta	-1.42
Analysts	Strong Sell
Price Target	$18.00